Biomarkers in Women with Breast Cancer: I: CEA, CA 15.3, CA 27-29, BRCA1, and BRCA2 Predictive Value.

Authors

  • Amina Hamed Alobaidi  Departments of Biochemistry, Medicine and Surgery, Tikrit University College of Medicine, Tikrit, Iraq
  • Arzo Jalaly  Departments of Biochemistry, Medicine and Surgery, Tikrit University College of Medicine, Tikrit, Iraq
  • Abdulghani Mohamed Alsamarai  Departments of Biochemistry, Medicine and Surgery, Tikrit University College of Medicine, Tikrit, Iraq

Keywords:

Breast, Cancer, CEA, CA 15-3, CA 27-29, BRCA1, BRRCA2, ROC, AUC.

Abstract

Background: Breast cancer is the most cancer affecting women worldwide and to date most of the investigated biomarkers are with low sensitivity and specificity in early diagnosis of primary cancer.
Aim: In the present study the relationship of tumor marker panel and breast cancer in an Iraqi population was investigated.
Patients and Methods: 100 women with breast cancer and 100 healthy controls were included in the study. All patients and control groups serum samples were subjected for determination of CEA, CA15.3, CA27.29, BRCA1, and BRCA2.
Results: Serum mean values of CA 15-3, CA 27-29, CEA, BRCA1 and BRCA2 were significantly higher in women with breast cancer than in controls. OR and relative risk confirm the association between serum increase of the five markers to breast cancer. AUC of ROC indicated the high sensitivity of their determination in breast cancer.
Conclusion:the present study show evidence that serum CA15-3, CA27-29 and CEA simultaneous determination arepotintial markers for early diagnosis of breast cancer metastasis and treatment minitoring.

References

  1. Bray,F., McCarron,P., &Parkin,D.M. The changing global patterns of female breast cancer incidence and mortality.Breast Cancer Res.2004; 6, 229-239.
  2. Chung L, Moore K, Phillips L, etal.Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Research 2014;16:R36
  3. Chung L, Baxter RC. Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays. Expert Rev Proteomics 2012;9:599-614.
  4. Li M, Kang JW, Sukumar S, Dasari RR, Barman I. Multiplexed detection of serological cancer markers with plasmon-enhanced Raman spectroimmunoassay. ChemSci 2015; DOI:10.1039/c5sc01054c.
  5. Ghasabeh HR, Keyhanian S. Relatioship between tumor marker CEA and CA 15-3 and recurrence breast cancer.J Paramedical Sci 2013;4:16-18.
  6. Pultz1 BA, Luz FAC, Faria PR, Oliveira APL, Araújo RA, Silva MBB. Far Beyond the Usual Biomarkers in Breast Cancer: A Review. 2014; 5(7): 559-571. doi: 10.7150/jca.8925.
  7. Weigel MT, Dowsett M. Current and emerging biomarkers in b reastcancer:prognosis and prediction. Endocrine Related Cancer 2010;17:R245-R262.
  8. Hammond MEF, Hayes DF, Dowsett M, Allred DC, et al. American Society for Clinical Oncology/ College of American Pathologist guideline recommendations for immunohistochemical testing of estrogen and progesteronreceptorsin breast cancer. J ClinOncol 2010;28:2784-2795.
  9. Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Intern J Proteomics 2011;volume 2011, Article ID 343582,9 pages.
  10. Dixon M. Breast cancer: diagnosis and management' Elsevier Health Sciences, 2000
  11. Duffy MJ.CA15-3 and rerated mucins as circulating markers in breast cancer. Ann clinBiochem 1999;36:579-86.
  12. Reddish MA, Helbrecht N, Almeida AF, Madiyalakan R, Suresh MR, Longenecker BM. Epitope mapping of MabB27 .29 within the peptide core of the malignant breast carcinoma-associatedmucin antigen coded for by the human MUC 1 gene. J Tumor marker Oncol 1992;7:19-27.
  13. Chan DW, Beveridge RA, Muss H, FritscheHA,Hortobagyi G, Theriault R, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer reculrence in patients with stage II and stage III disease. J ClinOncol 1997 ;15:2322-8.
  14. O'Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF, et al. An evaluation of preoperative cAl5.3 measurement in primary breast carcinoma. Br J Cancer 1995;7l:1288-91 .
  15. Bormer,O.P. Immunoassays for carcinoembryonic antigen: specificity and interferences. Scand. J. Clin. Lab Invest 53, 1-9 (1993).
  16. Nap, M., Hammarstrom,M.L. ,Bormer, O., Hammarstorm,S.,Wagener,C.,Handt, S., Schreyer,M., Mach, J. P. , Buchegger, F., von Kleist, S., & .Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen. Cancer Res 1992; 52, 2329-2339.
  17. Duffy MJ. Serum tumor markers in breast cancer:Are they of the clinical value ? Clin Chem 2006;52:345-351.
  18. Yerushalmi R, Tyldesley S, Kennecke H, et al . Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with oucome .Annals Oncology 2011;doi:10.1093/annonc/mdr154.
  19. Anonymous. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology .J Clin Oncol 1996;14:2843-77.
  20. Horobin JM, Browning MCK, McFarlane NP, Smith G, Preece PE, Wood RA, et al. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer. J R Coll Surg Edinb 1991;36:219–21.
  21. Duffy MJ, Duggan C, Keane R, Hill ADK, McDermorr E, Crown J, et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. ClinChem 2004;50:559–63.
  22. Jager W. Disseminated breast cancer: does early treatment prolong survival without symptoms? [Abstract]. Breast 1995;4: 65.
  23. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by ‘early’ salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 1997;76:1106–11.
  24. Nicolini A, Carpi A, Michelassi C, Spinelli C, Conte M, Miccoli P, et al. “Tumor marker guided” salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. BiomedPharmacother 2003;57:452–9.
  25. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S. Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer ChemotherPharmacol 1994;35:80–3.
  26. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977;13:89–94.
  27. Kurebayashi J, Nishimura R, Tanaka K, Kohno N, Kurosumi M, Moriya T, et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer 2004;11:389–95.
  28. Kumar R, Kumar AN, Srivastava A. Breast cancer tumor markers. J Solid Tumor 2012;2:43-46.
  29. Ebeling FG, Stieber P, Utch M, Nagel D, Konecny GE, Schmit UM , Fateh-Mghadam A and Seidel D. Serum CEA and CA15.3 as prognostic factors in primary breast cancer , Br J Cancer 2002 ; 22: 86 (8): 1217-1222.
  30. Verring A, Clouth A, Ziolkowski Pand Oremek M. Clinical Usefulness of Cancer Markers in Primary Breast Cancer , ISRN Pathology; Volume 2011 (2011), Article ID 817618, 4 Pages .
  31. Atoum M, Nimer N, Abdeldyem S, Nasr H. Relation among serum CA15.3 Tumor marker , TNM staging ,and Estrogen Receptor Expression in Benign and Malignant breast lesion , Asian Pacific J Cancer Prev 2012;13:875-860.
  32. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, Alessandro RD, Carone MD, Cicchetti A, Ricciotti A , Venturo I, Perri P, Filippo FD, Cognetti F , Botti C , and Roselli M. A Re-Evaluation of Carcinoembryonic Antigen(CEA) as a Serum Marker for Breast CancerA Prospective Longitudinal Study ,Clin cancer Res August 2001; 7:2357.
  33. Chung L, Moore K, Phillips L, etal.Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Research 2014;16:R36
  34. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer:prognosis and prediction.Endocrine Related Cancer 2010;17:R245-R262.
  35. American Society of Clinical Oncology.1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J ClinOncol 1.998:16:793-5.
  36. Gion M , Mione R, Leon AE, and Dittadi R. Comparion of the Diagnostic Accuracy of CA27.29 and CA15.3 in Primry Breast Cancer. Clinical Chemistry 1999; 45:630 – 637.
  37. Al-Hussain R, Kathaem EM, Baker LN, Assi SH , Abdulbaqi SS , Kalaf RK. Early detection of Breast Cancer by Tumor Marker CA15.3 , CA 27.29 and relationship with P53 and Vitamin D. J Biotech Res Center 2014;8:59-65.
  38. Correale M, Abbate l, Gargano G, Catino A, Dragone CD, Musci MD, et ai. Analytical and clinical evaluation of a new tumor marker in breast cancer: CA27.29. lnt .l Biol Markers 1992:7:43-6.
  39. Rodriguez de Paterna L, Amaiz J,Estenoz J, Ortuno B, lanzos E, Study of serum tumor markers CEA, CA15.3 and CA27'29 as diagnostic parameters in patients with breast carcinoma int J Biol Markers 1995;10:24 -9.
  40. Jensen lL, Maclean GD, Suresh MR, Almeida A, Jette D, Lloyd S, et e!. possible utility of serum determinations of CA15.3 and CA27.29 in breast cancer management. int J Biol Markers 1991; 6:1-6.
  41. Hayes DF, Zurawski VR, Kufe D. Comparison of circulating CA15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol1986;4:1542-1550.
  42. Devine PL, Duroux MA, Quin RJ, McGuickin MA, Joy GJ, Ward BG, Pollard CW. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.Breast Cancer Res Treat 1995;34:245-251.
  43. Eastbrook A, Chen J, Oster M, Salinen R, Yemul S, Leon J. Clinical value of BCA 225: a new breast cancer serum marker. J Tumor Marker Oncol 1994;9:111-118.
  44. Gion M, Mione R, Nascimben O, Valsecchi M, GaTTI C, Leon A, Bruscagnin G. The tumor associated antigen CA15.3 in primary Breast cancer. Evaluation 667 cases. Br. J Cancer 1991.63:809-13.
  45. Bon GG, von Mensdorff-Pouilly S, Kenemans P. van Kamp GJ, Verstraeten RA, Hilgers I, et al. Clinical and technical evaiuationof ACS-BR serum assay of MUCl gene-derived glycoprotein in breast cancer, and comparison wlth cA15.3 assays clinchem1997;43:58$-93.
  46. Dixon AR, Price MR, Hand CV, Sibley PE, Selby C, Blamey RW. Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer. A comparison with CA15.3. Br J Cancer 1993;68:947–9.
  47. Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA15.3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207–14.
  48. Kallioneimi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen M, Koivula T, et al. Serum CA15.3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 1988;58:213–5. 55 28. Miserez AR, Gu¨nes I, Mu¨ller-Brand J, Walther E, Fridrich R, Macke H, et al. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA15.3. Eur J Cancer 1991;27:126–31.
  49. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC. Evaluation of CA M26, CA M29, CA15.3 and CEA as circulating tumor markers in breast cancer patients. Tumor Biol 1991; 12:82–90
  50. Molina R, Filella X, Mengual P, Prats M, Zanon G, Daniels M, Ballesta AM. MCA in patients with breast cancer: correlation with CEA and CA15.3. Int J Biol Markers 1990;5:14–21.
  51. Crippa F, Bombardieri E, Seregni E, Castellani MR, Gasparini M, Maffioli L, et al. Single determination of CA15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer. J Nucl Biol Med 1992;36:52–5.
  52. Colomer R, Ruibal A, Genolla` J, Rubio D, Del Campo JM, Bodi R, Salvador L. Circulating CA15-3 levels in the postsurgical follow-up of breast cancer patients in non-malignant diseases. Breast Cancer Res Treat 1989;13:123–33.
  53. Soletormos G, Nielsen D, Schioler V, Skovsgaard T, Winkel P, Mouridsen HT, Dombernowsky P. A novel method for monitoring high-risk breast cancer with tumor markers: CA15.3 compared to CEA and TPA. Ann Oncol 1993;4:861–9.
  54. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995;36:41–8.
  55. Molina R, Jo J, Filella X, Zamon G, Palisa J, Munoz M,et al.c-erbB-2 oncoprotein, CEA and CA 15-3 in patients with breast cancer. Breast Cancer Res Treat 1998;51:109–19.
  56. Canizares F, Sola J, Perez M, Tovar I, De Las Heras M, Salinas J, et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. TumourBiol2002;22:273–81.
  57. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002;22:1217–22.
  58. Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, et al. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 2003;23:1035–42.
  59. Samy N, Ragab HM, El Maksoud NA, Shaalan M. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomark 2010;6(2):63-72.
  60. Lumachi F, Basso SM, Bonamini M, Marzano B, Milan E, Waclaw BU, et al. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer. Anticancer Res 2010;30(6):2331 2334.
  61. Mariani L, Miceli R, Michilin S, Gion M. Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers 2009;14(2):130-136.
  62. Lumachi F, Basso SM, Brandes A, et al. Relationship Between Tumor Markers CEA and CA 15-3,TNM Staging, Estrogen Receptor Rate and MIB-1 Index in Patients with pT1-2 Breast Cancer. Anti cancer research 2004; 24: 3221 3224
  63. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Annals of Oncology. 2008 Apr;19(4):675-681. Available from: 10.1093/annonc/mdm538
  64. Gion M, Mione R, Leon AE, Luftner D,; Molina R, Possinger K, Robertson JF: CA 27.29: a valuable marker for breast cancer management. A confi rmatory multicentric study on 603 cases. Eur J Cancer 2001; 37: 355–363.
  65. Molina R, Barak V, Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. Tumor Biol 2005 ;26:281–293 DOI: 10.1159/000089260
  66. Nishimura R, Nagao K, Miyayama H , Matsuda M , Baba KI, Matsuoka Y, et al. Elevated serum ca15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. Breast Cancer 2003; 10(3): 45-52.
  67. Serdarevi? N, Mehanovi? S. The possible role of tumor antigen CA 15-3, CEA and ferritin in malignant and benign disease. J Health Sci 2012;2:138-143.
  68. Chang, HJ, Yang MJ, Yang YH, Hou MF, Hsueh EJ, Lin SR. MMP13 is potentially a new tumor marker for breast cancer diagnosis. Oncol Rep. 2009;22:1119-1127.
  69. Zheng G, Patolsky F, Cui Y, Wang WU, Leiber CM. Multiplexed electrical detection of cancer markers with nanowire sensor array. Nat Biotechnol 2005;23:1294-1301.
  70. Tong D, Schneeberger C, Czerwenka K, Schmutzler RK, Speiser P, et al . Messenger RNA Determination of Estrogen Receptor, Progesterone Receptor, pS2, and Plasminogen Activator Inhibitor-1 by Competitive Reverse Transcription-Polymerase Chain Reaction in Human Breast Cancer. Clin Cancer Res 1999;5: 1497-1502.
  71. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J and Baselga J. Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells. Cancer Res 2001; 61: 4744–4749.

International Journal of Scientific Research in Science, Engineering and Technology

Downloads

Published

2015-08-30

Issue

Volume 1, Issue 4, July-August-2015

Section

Research Articles

License

Copyright (c) IJSRSET

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Amina Hamed Alobaidi, Arzo Jalaly, Abdulghani Mohamed Alsamarai, " Biomarkers in Women with Breast Cancer: I: CEA, CA 15.3, CA 27-29, BRCA1, and BRCA2 Predictive Value., International Journal of Scientific Research in Science, Engineering and Technology(IJSRSET), Print ISSN : 2395-1990, Online ISSN : 2394-4099, Volume 1, Issue 4, pp.442-449, July-August-2015.